CareCube Solutions Limited

Product: 
Life Sciences
Status: 
Closed
Sector: 
Digital workflow
Aim of funding: 
Seed
HMRC Advance Assurance received: 
Yes

CareCube Solutions Limited

Description: 

Care Cube Solutions Ltd (‘CCSL’) is a networked digital workflow system designed by cardiologists for users to simplify and centralise the complex tracking of patient flow in cardiology departments. In doing so, the technology seeks to safeguard patients from human error, and also assists hospitals to optimise resources via efficient time management.

The CCSL solution interacts with existing hospital systems such as the PAS (Patient Administration System) and EPR (Electronic Patient Records) and thus ensures patients, nurses and consultants have real-time information to keep all parties informed of the status of a patient continuously whilst they are on-site, thereby providing an unrivalled patient experience and outcome improvement.

CCSL was installed in the Liverpool Heart and Chest Hospital (LHCH) in April 2016 and has become the flagship NHS reference centre for potential future CCSL clients. The new reference centre allows future clients to see the system ‘live’ in the UK’s #1 cardiology centre for patient care and safety.

CCSL seeks to meet a clear unmet clinical in enabling hospitals to adopt new technologies and new ways of working to tangibly improve efficiency and maintain reductions in wasted resource.

Opportunity: 

CCSL seeks to meet a clear unmet clinical in enabling hospitals to adopt new technologies and new ways of working to tangibly improve efficiency and maintain reductions in wasted resource.

The Company has estimated that the target market size in Europe for their cardiology solution would be around 910 centres based on 1.8 centres per million of population (this extrapolation is calculated on the number of centres the UK has currently based on its population size) with the United States having 580 applicable centres.

Both Europe and the US face exactly the same challenges with the requirement for consistently high standards in the clinical delivery of cardiology. CCSL recognises there is an unmet clinical need and its early market research with the leading centres in both Sweden and Finland have both expressed  strong interest in utilising the Company’s solution.

It is anticipated that by the end of 2018, CCSL will be running in 22 centres across the UK and Northern Europe; during this time, a Med Tech channel partner will be engaged to accelerate commercialisation across the major European/US markets, with discussions commencing in Q2 2016.

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.